Physician profile
Devin Singh
NPI 1609150895
$3,902.15
in general payments reported to CMS, 2019-2025
20 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $57.99 · 2021: $231 · 2022: $107 · 2023: $495 · 2024: $1,529 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,273 · Education: $61.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.24 |
| Education | $61.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $664.54 | 2023-2025 | Miebo, Xiidra, Infuse |
| Oyster Point Pharma, INC. | $480.22 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $441.96 | 2022-2025 | Lumigan, Vuity |
| Alcon Vision LLC | $411.81 | 2023-2025 | Rocklatan, Rhopressa, Tryptyr |
| Harrow Eye, LLC | $292.23 | 2024-2025 | Vevye |
| Glaukos Corporation | $270.27 | 2024 | Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $239.08 | 2023-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $230.50 | 2019-2021 | |
| Dompe US, INC. | $164.01 | 2024-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $121.82 | 2024 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.68 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $114.76 | 2024-2025 | Xdemvy |
| Rxsight INC | $101.28 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $72.02 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $56.55 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.30 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $27.54 | 2025 | Eylea, Eylea Hd |
| Astellas Pharma US INC | $26.53 | 2024 | Izervay |
| Genentech USA, INC. | $20.22 | 2024 | Vabysmo |
| Allergan, INC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.